ArticleAmerican journal of translational research2026
Effect of calcium and vitamin D supplementation on recurrence of benign paroxysmal positional vertigo in osteoporotic patients.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether calcium and vitamin D supplementation can reduce the recurrence of benign paroxysmal positional vertigo (BPPV) and improve quality of life in patients with osteoporosis.
methodsIn this retrospective study, 334 patients with primary osteoporosis and posterior semicircular canal BPPV were included and divided into three groups based on treatment: Group A (n = 103; intravenous calcium gluconate infusion [20 mL diluted in 250 mL 5% glucose per day for 15 days per course, four courses total]), Group B (n = 112; intramuscular injection of vitamin D
resultsAt 6 months post-treatment, DHI scores were 40.57 ± 3.67 in Group A, 41.25 ± 4.11 in Group B, and 32.63 ± 2.11 in Group C. The score in Group C was significantly lower than those in Groups A and B (P < 0.001), while Groups A and B showed comparable scores (P = 0.2991). Additionally, Group C exhibited a significantly lower BPPV recurrence rate at 12 months post-treatment (P = 0.030 vs. Group A; P = 0.021 vs. Group B) and 24 months post-treatment (P = 0.016 vs. Group A; P = 0.017 vs. Group B). Serum calcium (P < 0.001 vs. both Groups A and B) and vitamin D levels (P = 0.0191 vs. Group A; P = 0.0423 vs. Group B) were significantly higher in Group C compared with the other two groups. Moreover, Group C showed improved bone metabolism, as indicated by higher procollagen type I N-terminal propeptide (P1NP) levels (P < 0.05) and lower beta-crosslaps (β-CTX) levels (P < 0.05) than the other two groups. Quality-of-life scores were significantly improved in Group C across several domains, including physical functioning, role-physical, role-emotional, mental health, and social functioning (all P < 0.001). Notably, adverse effects were comparable among the groups (all P > 0.05, Fisher's exact test).
conclusionCombined calcium and vitamin D supplementation may reduce BPPV recurrence and improve quality of life in patients with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.